5.35
-0.16 (-2.90%)
| Previous Close | 5.51 |
| Open | 5.34 |
| Volume | 2,503 |
| Avg. Volume (3M) | 21,420 |
| Market Cap | 53,325,484 |
| Price / Earnings (TTM) | 1.58 |
| Price / Book | 29.88 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -37,468.63% |
| Diluted EPS (TTM) | 3.38 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Quarterly Earnings Growth (YOY) | -19.50% |
| Total Debt/Equity (MRQ) | 26.43% |
| Current Ratio (MRQ) | 2.45 |
| Operating Cash Flow (TTM) | -19.88 M |
| Levered Free Cash Flow (TTM) | -11.33 M |
| Return on Assets (TTM) | -135.82% |
| Return on Equity (TTM) | -485.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Serina Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | -5.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -1.00 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 63.85% |
| % Held by Institutions | 3.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Waverly Advisors, Llc | 31 Mar 2025 | 67,492 |
| Keel Point, Llc | 31 Mar 2025 | 17,774 |
| Piscataqua Savings Bank | 30 Jun 2025 | 28 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MOREADITH RANDALL | - | 5.21 | -4,304 | -22,436 |
| Aggregate Net Quantity | -4,304 | |||
| Aggregate Net Value ($) | -22,436 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 5.21 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MOREADITH RANDALL | Officer | 20 Aug 2025 | Sell (-) | 2,077 | 5.20 | 10,800 |
| MOREADITH RANDALL | Officer | 20 Aug 2025 | Option execute | 2,077 | - | - |
| MOREADITH RANDALL | Officer | 18 Aug 2025 | Sell (-) | 2,227 | 5.23 | 11,636 |
| MOREADITH RANDALL | Officer | 18 Aug 2025 | Option execute | 2,227 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |